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Ganfort is more cost effective than Duotrav and Xalacom in UK,
Denmark, Sweden, Norway, Finland, France, Italy and Spain.
Thus, the cost per percentage reduction in IOP is lower for
Ganfort compared to Duotrav and Xalacom.
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OBJECTIVES: To assess effectiveness, cost and cost-effectiveness
of Lucentis versus current medical practices in age relatedmacular
degenerescence in France. METHODS: A simulation decision
framework over 1-year time horizon compares a new speciﬁc
agent “Lucentis” versus usual care using two effectiveness end-
points: “vision acuity improvement rate” (greater than 15 letters
at the EDTRS scale) and “rate of legal blindness avoided”. The
two decision trees include various sequences of current therapies
and laser treatment, including or not Lucentis. Data sources come
from clinical data, literature and expert opinions for variability
and uncertainty assumptions. Probabilistic sensitivity analyses
were conducted taking into account speciﬁc distribution laws for
each cost and effectiveness parameters. French costing data
include direct medical costs, adaptative costs and social allowance
in case of blindness. RESULTS: Rate of visual acuity improve-
ment: Lucentis as ﬁrst line agent is signiﬁcantly more effective
(p < 0.001), providing greater treatment success rate of visual
acuity improvement than usual care (48.8% versus 33.9.1%).
Direct medical costs is 9123 Euros over 1 year for Lucentis
compared to 7604 Euros for usual care.Mean cost-effectiveness is
18721 Euros /success for Lucentis versus 22543 Euros/success for
usual care (p < 0.001). Rate of legal blindness avoided: Lucentis as
ﬁrst line agent is signiﬁcantlymore effective (p < 0.001), providing
greater treatment success rate of legal blindness avoided than
usual care (99.6% versus 93.1%). Direct medical costs is 10493
Euros over 1 year for Lucentis compared to 8016 Euros for usual
care. Mean cost-effectiveness is 10526 Euros /legal blindness
avoided for Lucentis versus 8607 Euros/legal blindness avoided
for usual care.CONCLUSION:Lucentis signiﬁcantly improve the
rate of visual acuity improvement and reduces the rate of legal
blindness. Lucentis is signiﬁcantly more cost-effective than usual
care in term of visual acuity improvement.
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OBJECTIVES:To compare the lifetime costs of complications due
to posterior capsule opaciﬁcation after cataract surgery in three
types of IOLs, namely two hydrophobic lenses SA60AT, AR40E
and one hydrophilic lens the XL-Stabi. METHODS: Costs were
estimated from the results of a retrospective study of patients who
underwent cataract surgery in 2001 and 2002 as well as from data
in the literature. Data were analysed after a minimum of 3 years
post-surgery using Kaplan-Meier survival curve analysis with the
end event being time to Nd:Yag laser capsulotomy. Costs were
calculated using two methods of extrapolation. The economic
perspectivewas that of the French Sickness Fund.RESULTS:After
3 years of follow-up, the percentage of patients who had under-
gone Nd:Yag laser capsulotomy was 12.0% with the SA60AT,
25.2% with the AR40E and 51.0% with the XL-Stabi lenses
(P < 0.001). The total cost of capsulotomy and management of
complications per patient lifetimewas estimated to be 142.6 Euros
for SA60AT, 273.4 Euros for AR40E ad 347.1 Euros for XL-Stabi
using the ﬁrst method of extrapolation, while using the second
method of extrapolation, the costs were 242.8, 317.6 and 347.2
Euros, respectively. CONCLUSION: Lower costs for cataract
surgery and management of related complications were observed
with the SA60AT and AR40E IOL’s with the lowest overall costs
being observed in the SA60AT lens.
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OBJECTIVES: Whilst the sight-restoring effects of surgery in
patients with severe bilateral cataract are obvious, there has been
a signiﬁcant trend over the last two decades of performing cata-
ract surgery at an increasingly earlier stage with a rising propor-
tion having 6/12 vision or better at the time of listing. In these
circumstances, the cost-effectiveness of surgery is open to ques-
tion. Therefore, this study evaluated the cost-effectiveness of
ﬁrst-eye cataract surgery compared to no surgery from a Health
Service and Personal Social Services perspective. METHODS: An
economic evaluation was undertaken alongside a randomised
controlled trial of ﬁrst-eye cataract surgery in secondary care
ophthalmology clinics. A total of 306 women over 70 years old
with bilateral cataracts were randomised to cataract surgery
(expedited, approximately 4 weeks) or control (routine, 12
months wait). Seventy-ﬁve percent of participants had baseline
acuity of 6/12 or better. Health and social service contacts were
collected at individual patient level from diaries ascertained at 3
and 9 months via telephone interviews, and at 6 and 12 months
via face-to-face interviews. Outcomes included falls and Quality
Adjusted Life Years (QALYs). RESULTS: The mean difference in
cost between the operated and control group was 2004 (boot-
strapped)(95% CI 1363 to 2833, p < 0.001) over one year
(UK  2004). However, those in the operated group experi-
enced, on average, 0.456 fewer falls, representing an incremental
cost per fall prevented of4390. The bootstrapped mean gain in
QALYs per patient was 0.056 (95% CI 0.006 to 0.108,
p < 0.001). The incremental cost utility ratio was 35,704,
above the currently accepted UK threshold level of willingness to
pay per QALY of30,000. However, in a model of the costs and
beneﬁts over patients’ expected lifetime, the incremental cost per
QALY was 13,172, under conservative assumptions. CON-
CLUSION: First-eye cataract surgery, whilst cost-ineffective over
the trial period, appeared cost-effective over participants’
remaining lifetime.
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OBJECTIVES: After 45–50 years of age, the vast majority of
people have presbyopia, a loss of the ability to focus on near
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objects. This, and the common need for distance vision correc-
tion, often results in the use of eyeglasses. The objectives of this
survey were to collect data in ﬁve European countries (France,
Germany, Italy, Spain and the UK) on the associated societal costs
of wearing spectacles and subject willingness to pay to be free of
spectacles. METHODS: A sample of citizens over 45 years of age
and wearing glasses was selected using a quota method (age,
gender, occupation). Telephone interviews (22 questions) were
conducted using a Computer Aided Telephone Interviewing
system. RESULTS: A total of 4157 subjects were interviewed
across the countries. 38.4% were >65 years old and 55.8% were
female. In all countries, prescribed glasses were mainly mono-
focal (49.7–72.8%), except for France (29.8%). Spectacles were
replaced every 2 or more years by 70.4% of the subjects and the
average expenditure exceeded €145 per pair in 62.9% of the
cases. Replacement frequency was higher in the UK and expen-
ditures were higher in France. The 3 main daily tasks requiring
glasses were reading (60.4%), watching TV (33.6%) and shop-
ping (28.8%). Across all the countries, 45.3% of the subjects
declared that they would be willing to pay at least a part of the
cost to avoid spectacles. Men and people less than 64 years old
had a higher willingness to pay to be free of spectacles. CON-
CLUSION: Citizens living in a country where private insurance
reimburses a signiﬁcant portion of eyeglass costs bought more
expensive spectacles. A higher spectacle replacement frequency is
associated with a lower price. About half the European citizens
would be willing to pay at least a part of the cost to be free of
spectacles, especially men and people <64 years of age.
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OBJECTIVES: Develop a health economic model to measure the
standard of care costs in the UK (UK) associated with progres-
sion of primary open angle glaucoma. METHODS: We used
Monte Carlo techniques to model the cost of a simulated cohort
of 600 patients with Mean Deviation (MD) score progression
over four years. MD scores were used to estimate resource utili-
zation for the cohort using regression equations from an analysis
of the relationship between resources and MD score in the worst
eye from a European chart review of glaucoma patients (N = 194
from UK, Italy, France, Germany and Austria). Both medical
(number of ofﬁce visits, visual ﬁeld exams, trabeculoplasties and
trabeculectomies) and pharmacy resources (number of glaucoma
medications) were included in the model. UK NHS reference
costs were applied to the medical resource utilization estimates;
medication costs from the British National Formulary were
applied to the pharmacy utilization estimates. MD scores were
also used to predict utility scores based on a regression analysis
of utility scores among glaucoma patients in Sweden; the quality-
adjusted-life years (QALYs) over four years was modeled. A
probabilistic sensitivity analysis was also performed. RESULTS:
The four-year cost for the cohort was 932 per patient (196 in
pharmacy costs and 736 in medical costs) with 2.96 QALYs
accumulated over four years. CONCLUSION: Glaucoma pro-
gression as evidenced by worsening MD scores is associated with
a loss in quality of life and substantial costs over four years of
follow-up. Managing the disease and delaying progression has
the potential to improve quality of life and reduce costs among
patients with progression.
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OBJECTIVES: Study the oxidative status in patients with
primary open-angle glaucoma (POAG) in order to evaluate
if antioxidant supplementation may beneﬁt these patients.
METHODS: Enzimatic-colorimetric biochemical assays for
determining peroxidative (malondialdehyde, MDA), antioxidant
(total antioxidan statust TAS) and nitrosative (nitric oxide, NO)
activities were carried out in the aqueous humour from one
hundred and twenty patients operated alternatively for primary
open angle glaucoma (POAG-G) or cataracts (CAT-G). A com-
parison between groups was done by using the Student T test by
means of the SPSS statistical package. RESULTS: The MDA
levels were signiﬁcantly higher (p < 0.001) in the aqueous
humour from the POAG-G than in the CAT-G. The TAS levels
were signiﬁcantly lower (p < 0.01) in the POAG-G samples than
in the comparative ones. NO levels were signiﬁcantly higher
(p < 0.05) in the POAG-G samples than in the CAT-C. CON-
CLUSION: The relationship between pro-oxidant and antioxi-
dant activities in the aqueous humour was strongly dysbalanced
towards oxidative capacity in the glaucoma patients. All data
suggest that oxidative stress has to be considered among the
etiopathogenical mechanisms of advanced glaucoma. The possi-
bility remains that antioxidant supplementation may beneﬁt the
glaucoma cases displaying lower antioxidant capacity in the
described laboratory tests.
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OBJECTIVES: To estimate the net health beneﬁts of intravitreal
VEGF inhibitors indicated for patients with NV-AMD with dif-
fering baseline risks for cardiovascular events. METHODS: A
decision-analytic risk-beneﬁt model with a 10-year horizon was
developed to jointly assess the intended and unintended effects of
pegaptanib and of ranibizumab. Input data were abstracted from
the results of published randomized controlled trials comparing
active comparator to usual care (UC). Intended effects of treat-
ment were quantiﬁed using the relative risk (RR) of progression
to legal blindness (<20/200 visual acuity [VA]) in the better
seeing-eye. Unintended effects included key Anti-Platelet Trial-
ists’ Collaborative events (APTC: fatal or non-fatal myocardial
infarction, cerebrovascular accident, or death from unknown
or vascular cause) or severe non-ocular hemorrhages (NOH).
Ranibizumab treatment was associated with RRs of 0.27 (pro-
gression to legal blindness; 95% conﬁdence interval: 0.21–0.36),
2.2 (APTC events; 0.78–6.30) and 5.5 (severe NOH; 0.7–46.3).
Pegaptanib was associated with RRs of 0.65 (progression to legal
blindness; 0.54–0.79), 1.5 (APTC events; 0.4–5.3) and 0.8
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